Pulmatrix (NASDAQ:PULM – Get Free Report) issued its quarterly earnings results on Friday. The biotechnology company reported ($0.54) earnings per share for the quarter, Zacks reports. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.
Pulmatrix Price Performance
Shares of NASDAQ:PULM traded down $0.21 during trading on Friday, hitting $7.40. 1,748 shares of the company’s stock were exchanged, compared to its average volume of 131,939. The business’s 50-day simple moving average is $7.44 and its 200 day simple moving average is $5.13. The company has a market cap of $26.99 million, a price-to-earnings ratio of -2.80 and a beta of 1.66. Pulmatrix has a 52-week low of $1.56 and a 52-week high of $10.40.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of Pulmatrix in a research note on Sunday, January 5th. They set a “hold” rating on the stock.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- 3 Stocks to Consider Buying in October
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What is the Nasdaq? Complete Overview with History
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- What is the S&P 500 and How It is Distinct from Other Indexes
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
